Court Deals Blow To Mylan In Norvasc Dispute

Law360, New York (July 2, 2007, 12:00 AM EDT) -- A district court has shot down Mylan Laboratories Inc.’s bid to require the U.S. Food and Drug Administration to relist Pfizer’s patent for Norvasc on its patent register in order for Mylan to hold onto its position as one of the few generic marketers of the blood pressure drug.

On Friday, Judge Ricardo M. Urbina of the U.S. District Court for the District of Columbia denied Mylan’s emergency motion for a temporary restraining order forcing Pfizer to put Norvasc back on its patent register, finding that...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.